Your session is about to expire
← Back to Search
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg for High Blood Pressure(GMRx2_ACT Trial)
GMRx2_ACT Trial Summary
This trial is investigating whether a triple low-dose combination therapy is more effective and has fewer side effects than dual combinations when treating high blood pressure.
GMRx2_ACT Trial Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowGMRx2_ACT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
GMRx2_ACT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical conditions does Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg help ameliorate?
"Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg can help patients who have cardiovascular issues, are at high risk for cardiovascular problems, or have dyslipidemias."
Are there other research papers that explore the effects of taking Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg?
"The first study of Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg was completed in 2012 at UT Southwestern Medical Center. As of now, 473 studies have been completed in total. Out of the 40 active clinical trials, a large number are based out of North Richland Hills, Texas."
In how many places is this particular clinical trial being conducted?
"There are 33 total sites for this ongoing clinical trial, including North Hills Medical Research (North Richland Hills, Texas), Suncoast Research Group (Miami, Virginia), and Meridian Clinical Research (Portsmouth, North Carolina, Virginls, Texas), Suncoast Research Group (Miami, Virginia), and Meridian Clinical Research (Portsmouth, North Carolina)."
Has the FDA cleared Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg for public use?
"Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg is in Phase 3 of clinical trials, so there is some data to support its efficacy and multiple rounds of data that suggest it is safe. Therefore, our team at Power has given it a score of 3."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger